Close Menu

NEW YORK (360Dx) – Multiple new technologies have emerged in recent years for isolating circulating tumor cells, some of which are now making more definitive moves towards the clinic.

Angle, a UK-based firm with a label-free system called Parsortix, announced last week, for example, that it has enrolled the first patient in its ANG-002 breast cancer clinical study, which is intended to support submission of Parsortix to the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.